Please login to the form below

Not currently logged in
Email:
Password:

ImmuNext

This page shows the latest ImmuNext news and features for those working in and with pharma, biotech and healthcare.

Lilly and ImmuNext deal focused on autoimmune diseases

Lilly and ImmuNext deal focused on autoimmune diseases

In return, ImmuNext will grant Lilly a worldwide licence to develop and commercialise the novel immunometabolism target. ... In addition, Lilly and ImmuNext will establish a three year research collaboration to support the target's development.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    625. Momenta. CSL. Licence. M230 immuno-modulator of Fc receptors. 600. ImmuNext.

  • Deal Watch December 2016 Deal Watch December 2016

    453. ImmuNext (US). Roche (Switzerland). Licence. Rights to develop and commercialise therapeutic products that agonise the VISTA (negative checkpoint regulator) signalling pathway. ... ImmuNext. Roche. $400m. Not disclosed. Products that agonise the

  • Pharma deals during September 2012 Pharma deals during September 2012

    Lebanese company Immunext is developing novel therapeutics that modulate the immune system to treat cancer, and has announced a deal with Janssen Biotech. ... Nanocyclix technology platform for kinase inhibitors. 168. ImmuNext / Janssen Biotech. Licence

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

APAC map
Pharmaceutical innovation in the APAC region
A first-of-its-kind study paints a vivid picture of the APAC region’s future...
Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...

Infographics